Cytek Biosciences, Inc.
CTKB- Exchange
- Nasdaq
- Industry
- Laboratory Analytical Instruments
- SEC CIK
- 0001831915
No open-market purchases or sales by Cytek Biosciences, Inc. insiders were filed in the last 90 days; 154 institutions reported holding it in 13F filings for Q2 2026, worth $361.0M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
13F holders, Q4 2023
Institutional positions in Cytek Biosciences, Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 105
- −2 vs. Q3 2023
- Shares held
- 78.9M
- +1.53M (+2.0%) vs. Q3 2023
- Total value
- $719.9M
- +$292.2M (+68.3%) vs. Q3 2023
- New holders
- 18
- 44 more added
- Sold out
- 20
- 29 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CTKB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 154 | $361.0M |
| Q1 2026 | 165 | $371.8M |
| Q4 2025 | 155 | $414.3M |
| Q3 2025 | 153 | $277.4M |
| Q2 2025 | 158 | $270.0M |
| Q1 2025 | 161 | $310.8M |
| Q4 2024 | 153 | $501.4M |
| Q3 2024 | 136 | $415.3M |
| Q2 2024 | 129 | $425.1M |
| Q1 2024 | 125 | $540.9M |
| Q4 2023 | 105 | $719.9M |
| Q3 2023 | 107 | $427.7M |
| Q2 2023 | 101 | $657.9M |
| Q1 2023 | 102 | $629.6M |
| Q4 2022 | 103 | $654.1M |
| Q3 2022 | 88 | $898.5M |
| Q2 2022 | 85 | $567.8M |
| Q1 2022 | 74 | $514.5M |
| Q4 2021 | 52 | $571.9M |
| Q3 2021 | 54 | $733.8M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Cytek Biosciences, Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| HHLR Advisors, Ltd.SuperinvestorHHLR Advisors (Hillhouse) | 6,657,030 | $60.7M | 1.22% | 00.0% | Unchanged |
| Ra Capital Management, L.P. | 6,809,404 | $62.1M | 0.97% | 00.0% | Unchanged |
| Vanguard Group Inc | 11,890,700 | $108.4M | 0.00% | +811,279+7.3% | Added |
| Brown Capital Management LLC | 12,016,325 | $109.6M | 1.64% | −1,544,155−11.4% | Reduced |
| BlackRock Inc. | 17,779,753 | $162.2M | 0.00% | +1,009,080+6.0% | Added |
| Millennium Management LLC | 0 | $0 | 0.00% | −427,954−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −296,900−100.0% | Sold out |
| SG Americas Securities, LLC | 0 | $0 | 0.00% | −188,813−100.0% | Sold out |
| Royce & Associates LP | 0 | $0 | 0.00% | −87,489−100.0% | Sold out |
| Man Group plc | 0 | $0 | 0.00% | – | Sold out |
| Quantbot Technologies LP | 0 | $0 | 0.00% | −46,452−100.0% | Sold out |
| Jump Financial, LLC | 0 | $0 | 0.00% | −43,404−100.0% | Sold out |
| Versor Investments LP | 0 | $0 | 0.00% | −33,900−100.0% | Sold out |
| Verition Fund Management LLC | 0 | $0 | 0.00% | −30,451−100.0% | Sold out |
| Y-Intercept (Hong Kong) Ltd | 0 | $0 | 0.00% | −19,234−100.0% | Sold out |
| Handelsbanken Fonder AB | 0 | $0 | 0.00% | −16,800−100.0% | Sold out |
| Sherbrooke Park Advisers LLC | 0 | $0 | 0.00% | −15,656−100.0% | Sold out |
| Walleye Capital LLC | 0 | $0 | 0.00% | −15,474−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −14,995−100.0% | Sold out |
| Bayesian Capital Management, LP | 0 | $0 | 0.00% | −14,950−100.0% | Sold out |
| LPL Financial LLC | 0 | $0 | 0.00% | −12,500−100.0% | Sold out |
| Allspring Global Investments Holdings, LLC | 0 | $0 | 0.00% | −4,803−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −404−100.0% | Sold out |
| Bessemer Group Inc | 0 | $0 | 0.00% | −366−100.0% | Sold out |
| Versant Capital Management, Inc | 0 | $0 | 0.00% | −286−100.0% | Sold out |